Author contribution
YS-H and KH prepared the manuscript and figures. YS-H and ST performed autopsy. TY, MK and TN performed molecular detection of the virus. YM analyzed the CT images. KF and MN cared the patient and prepared clinical data. KI designated this study.
References1 Caramaschi S, Kapp ME, Miller SE, et al. Histopathological findings and clinicopathologic correlation in COVID-19: a systematic review. Mod Pathol. 2021; 34: 1614-33. 2 Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018; 9. 3 Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020; 371: m3862. 4 Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020;383: 1827-37. 5 Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021; 384: 693-704. 6 Gandhi RT. The Multidimensional Challenge of Treating COVID-19: Remdesivir is a Foot in the Door. Clin Infect Dis. 2020. 7 Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020; 383: 2333-44. 8 Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.Lancet. 2021; 397: 1637-45. 9 Brown MJ, Alazawi W, Kanoni S. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021;385: 1147. 10 Gordon AC, Angus DC, Derde LPG. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. Reply. N Engl J Med. 2021;385: 1147-49. 11 Schaller T, Hirschbuhl K, Burkhardt K, et al. Postmortem Examination of Patients With COVID-19. JAMA. 2020; 323: 2518-20. 12 Yao XH, Luo T, Shi Y, et al. A cohort autopsy study defines COVID-19 systemic pathogenesis. Cell Res. 2021; 31: 836-46. 13 Bryce C, Grimes Z, Pujadas E, et al. Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Mod Pathol. 2021; 34: 1456-67. 14 Calabrese F, Pezzuto F, Fortarezza F, et al. Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists. Virchows Arch. 2020; 477: 359-72. 15 von Weyhern CH, Kaufmann I, Neff F, Kremer M. Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. Lancet. 2020; 395: e109. 16 Falasca L, Nardacci R, Colombo D, et al. Postmortem Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With and Without Comorbidities. J Infect Dis. 2020;222: 1807-15. 17 Adachi T, Chong JM, Nakajima N, et al. Clinicopathologic and Immunohistochemical Findings from Autopsy of Patient with COVID-19, Japan. Emerg Infect Dis. 2020; 26. 18 Okudela K, Hayashi H, Yoshimura Y, et al. A Japanese case of COVID-19: An autopsy report. Pathol Int. 2020; 70: 820-24. 19 Keshinro SO, Awolola NA, Adebayo LA, Mutiu WB, Saka BA, Abdus-Salam IA. Full autopsy in a confirmed COVID-19 patient in Lagos, Nigeria - A case report. Hum Pathol (N Y). 2021; 24: 200524. 20 Update to living WHO guideline on drugs for covid-19. BMJ. 2021; 374: n2219.